Schizophrenia bulletin open · 2025
Attitudes Driving Regional Differences in Long-Acting Injectable Antipsychotic Utilization for Schizophrenia among Healthcare Professionals, Patients, and Caregivers (ADVANCE): Results from a Multinational Survey Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Franzenburg Kelli R, Hansen Rolf, Suett Mark, Yaari Ayelet, Peyser Levin Aviva, Sergerie Martin, Kaplan Sigal, Sedigh Kameron, Heres Stephan, Sajatovic Martha
Аннотация
BACKGROUND: Long-acting injectable (LAI) antipsychotics improve adherence and reduce schizophrenia relapse rates vs oral antipsychotics (OAs) but remain underused. The ADVANCE study explored country-level differences in LAI use among healthcare professionals (HCPs), patients, and caregivers, to identify drivers of LAI use.
STUDY DESIGN: ADVANCE included participants from Australia, Canada, China, Germany, Israel, South Korea, Spain, and the United States. Eligible HCPs spent ≥25% of their time in direct patient care, managed an adult population of whom ≥10% have schizophrenia, and treated patients prescribed LAIs. Patients aged ≥18 years and caregivers of adults living with schizophrenia who had tried/been offered an LAI were included. Participants completed a 30-minute survey.
STUDY RESULTS: Systemic factors reported by HCPs (n = 791) associated with higher LAI use included being a physician vs nonphysician, having Hispanic/Latino/Spanish ethnicity, managing more adult patients with schizophrenia, and having more staff and nurse support. Nonadherence to OAs was the main HCP-reported reason for LAI recommendation. Patient characteristics, lack of available LAIs corresponding to OAs, and perceptions of patients' behavior were top reasons HCPs would not recommend an LAI. For patients (n = 470), symptom improvement and HCP recommendation, and for caregivers (n = 381), ease of injections, reduced hospitalizations, and fewer side effects were the main reasons for LAI acceptance. The top reason patients and caregivers declined LAIs was concern about side effects.
CONCLUSIONS: Results from ADVANCE demonstrate that systemic and attitudinal factors influence LAI use by HCPs, and these factors vary by country. Enhancing HCP-patient communication may improve LAI acceptance.
STUDY DESIGN: ADVANCE included participants from Australia, Canada, China, Germany, Israel, South Korea, Spain, and the United States. Eligible HCPs spent ≥25% of their time in direct patient care, managed an adult population of whom ≥10% have schizophrenia, and treated patients prescribed LAIs. Patients aged ≥18 years and caregivers of adults living with schizophrenia who had tried/been offered an LAI were included. Participants completed a 30-minute survey.
STUDY RESULTS: Systemic factors reported by HCPs (n = 791) associated with higher LAI use included being a physician vs nonphysician, having Hispanic/Latino/Spanish ethnicity, managing more adult patients with schizophrenia, and having more staff and nurse support. Nonadherence to OAs was the main HCP-reported reason for LAI recommendation. Patient characteristics, lack of available LAIs corresponding to OAs, and perceptions of patients' behavior were top reasons HCPs would not recommend an LAI. For patients (n = 470), symptom improvement and HCP recommendation, and for caregivers (n = 381), ease of injections, reduced hospitalizations, and fewer side effects were the main reasons for LAI acceptance. The top reason patients and caregivers declined LAIs was concern about side effects.
CONCLUSIONS: Results from ADVANCE demonstrate that systemic and attitudinal factors influence LAI use by HCPs, and these factors vary by country. Enhancing HCP-patient communication may improve LAI acceptance.